Ninety One North America Inc. Purchases 5,063 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Ninety One North America Inc. raised its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 74.1% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 11,892 shares of the company’s stock after acquiring an additional 5,063 shares during the quarter. Ninety One North America Inc.’s holdings in IDEXX Laboratories were worth $6,601,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of IDXX. Panagora Asset Management Inc. lifted its holdings in IDEXX Laboratories by 50.3% in the first quarter. Panagora Asset Management Inc. now owns 3,232 shares of the company’s stock valued at $1,768,000 after acquiring an additional 1,081 shares during the period. Raymond James Trust N.A. lifted its holdings in IDEXX Laboratories by 26.8% in the first quarter. Raymond James Trust N.A. now owns 1,624 shares of the company’s stock valued at $888,000 after acquiring an additional 343 shares during the period. Cetera Investment Advisers lifted its holdings in IDEXX Laboratories by 77.1% in the first quarter. Cetera Investment Advisers now owns 3,675 shares of the company’s stock valued at $2,010,000 after acquiring an additional 1,600 shares during the period. Moors & Cabot Inc. raised its stake in shares of IDEXX Laboratories by 3.0% in the first quarter. Moors & Cabot Inc. now owns 1,757 shares of the company’s stock worth $961,000 after buying an additional 52 shares during the period. Finally, Sequoia Financial Advisors LLC raised its stake in shares of IDEXX Laboratories by 15.6% in the first quarter. Sequoia Financial Advisors LLC now owns 992 shares of the company’s stock worth $543,000 after buying an additional 134 shares during the period. Institutional investors own 87.84% of the company’s stock.

Wall Street Analysts Forecast Growth

IDXX has been the topic of several recent research reports. StockNews.com raised IDEXX Laboratories from a “hold” rating to a “buy” rating in a research note on Wednesday, December 20th. Piper Sandler downgraded IDEXX Laboratories from an “overweight” rating to a “neutral” rating and set a $525.00 price objective on the stock. in a research note on Tuesday, January 30th. William Blair reaffirmed an “outperform” rating on shares of IDEXX Laboratories in a research note on Tuesday, April 9th. JPMorgan Chase & Co. raised their price objective on IDEXX Laboratories from $600.00 to $630.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 6th. Finally, The Goldman Sachs Group raised their price objective on IDEXX Laboratories from $500.00 to $650.00 and gave the stock a “buy” rating in a research note on Wednesday, January 17th. Three equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $591.50.

IDEXX Laboratories Price Performance

Shares of NASDAQ:IDXX traded up $1.86 during trading on Thursday, hitting $480.10. 163,024 shares of the company’s stock were exchanged, compared to its average volume of 424,065. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.57 and a quick ratio of 1.17. IDEXX Laboratories, Inc. has a 52-week low of $372.50 and a 52-week high of $583.39. The business’s 50-day simple moving average is $541.86 and its 200 day simple moving average is $508.71. The company has a market cap of $39.87 billion, a price-to-earnings ratio of 47.49, a PEG ratio of 3.77 and a beta of 1.26.

IDEXX Laboratories (NASDAQ:IDXX) last released its earnings results on Monday, February 5th. The company reported $2.32 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.12 by $0.20. IDEXX Laboratories had a return on equity of 71.66% and a net margin of 23.08%. The firm had revenue of $901.60 million during the quarter, compared to analysts’ expectations of $891.88 million. During the same quarter last year, the business posted $2.05 earnings per share. The firm’s revenue was up 8.8% on a year-over-year basis. As a group, equities analysts predict that IDEXX Laboratories, Inc. will post 11.15 EPS for the current year.

Insider Buying and Selling at IDEXX Laboratories

In other IDEXX Laboratories news, SVP George Fennell sold 8,198 shares of the firm’s stock in a transaction that occurred on Thursday, February 8th. The stock was sold at an average price of $573.87, for a total transaction of $4,704,586.26. Following the completion of the transaction, the senior vice president now owns 6,712 shares in the company, valued at approximately $3,851,815.44. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other IDEXX Laboratories news, CEO Jonathan Jay Mazelsky sold 12,000 shares of the firm’s stock in a transaction that occurred on Wednesday, February 7th. The stock was sold at an average price of $572.61, for a total transaction of $6,871,320.00. Following the completion of the transaction, the chief executive officer now owns 79,247 shares in the company, valued at approximately $45,377,624.67. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP George Fennell sold 8,198 shares of IDEXX Laboratories stock in a transaction that occurred on Thursday, February 8th. The stock was sold at an average price of $573.87, for a total value of $4,704,586.26. Following the completion of the transaction, the senior vice president now owns 6,712 shares of the company’s stock, valued at approximately $3,851,815.44. The disclosure for this sale can be found here. Insiders sold 43,524 shares of company stock worth $24,871,960 in the last quarter. 2.11% of the stock is owned by corporate insiders.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.